Your browser doesn't support javascript.
loading
Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout.
Knopp, Yvonne; Geis, Franziska K; Heckl, Dirk; Horn, Stefan; Neumann, Thomas; Kuehle, Johannes; Meyer, Janine; Fehse, Boris; Baum, Christopher; Morgan, Michael; Meyer, Johann; Schambach, Axel; Galla, Melanie.
Afiliação
  • Knopp Y; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Geis FK; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Heckl D; Pediatric Hematology and Oncology, Hannover Medical School, Hannover 30625, Germany.
  • Horn S; Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Neumann T; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Kuehle J; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Meyer J; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Fehse B; Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Baum C; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany; Presidential Office, Hannover Medical School, Hannover 30625, Germany.
  • Morgan M; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Meyer J; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany.
  • Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: schambach.axel@mh-hannover.de.
  • Galla M; Institute of Experimental Hematology, Hannover Medical School, Hannover 30625, Germany. Electronic address: galla.melanie@mh-hannover.de.
Mol Ther Nucleic Acids ; 13: 256-274, 2018 Dec 07.
Article em En | MEDLINE | ID: mdl-30317165
The recently discovered CRISPR/Cas9 system is widely used in basic research and is a useful tool for disease modeling and gene editing therapies. However, long-term expression of DNA-modifying enzymes can be associated with cytotoxicity and is particularly unwanted in clinical gene editing strategies. Because current transient expression methods may still suffer from cytotoxicity and/or low efficiency, we developed non-integrating retrovirus-based CRISPR/Cas9 all-in-one particles for targeted gene knockout. By redirecting the gammaretroviral packaging machinery, we transiently delivered Streptococcus pyogenes Cas9 (SpCas9) mRNA and single-guide RNA transcripts into various (including primary) cell types. Spatiotemporal co-delivery of CRISPR/Cas9 components resulted in efficient disruption of a surrogate reporter gene, as well as functional knockout of endogenous human genes CXCR4 and TP53. Although acting in a hit-and-run fashion, knockout efficiencies of our transient particles corresponded to 52%-80% of those obtained from constitutively active integrating vectors. Stable SpCas9 overexpression at high doses in murine NIH3T3 cells caused a substantial G0/G1 arrest accompanied by reduced cell growth and metabolic activity, which was prevented by transient SpCas9 transfer. In summary, the non-integrating retrovirus-based vector particles introduced here allow efficient and dose-controlled delivery of CRISPR/Cas9 components into target cells.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article